Positive final results in stroke
May 03, 2022 20:24 ET | Clinuvel Pharmaceuticals Limited
 ASX: XETRA-DAX:  Level 1 ADR:CUV UR9 CLVLY  EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
CLINUVEL to Trial Innovative Drug in Stroke
October 27, 2020 18:50 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of...
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference
September 14, 2020 00:58 ET | AB Science
Paris, September 14, 2020, 7am Press release AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference 50% of...
AB Science dévoile les résultats de son étude de Phase IIB/III dans les formes progressives de la Sclérose en Plaques à l’occasion du plus grand congrès international sur la sclérose en plaques
September 14, 2020 00:58 ET | AB Science
Paris, 14 septembre 2020, 7h00 Communiqué de Presse AB Science dévoile les résultats de son étude de Phase IIB/III dans les formes progressives de la Sclérose en Plaques à l’occasion du plus grand...
logo.png
Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST
August 07, 2020 11:34 ET | Arch Biopartners
TORONTO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it will host a webinar on August 18, 2020 at...
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
July 13, 2020 03:38 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA® is a...
Full Latin without Latin logo.png
SCENESSE® to be Prescribed in China
April 23, 2020 02:08 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) -- Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the...
Full Latin without Latin logo.png
Innovative drug launched for rare, isolating, “light intolerance” disorder
April 16, 2020 02:53 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or...
Full Latin without Latin logo.png
US FDA sets PDUFA date for SCENESSE®
January 10, 2019 07:29 ET | Clinuvel Pharmaceuticals Limited
Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in accordance with 21 CFR 314.101(a)Scientific exchange between...
CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
April 12, 2017 05:09 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and LEATHERHEAD, United Kingdom, April 12, 2017 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX:CUV) (XETRA:UR9) (OTC:CLVLY) today announced that it had reached agreement...